China SXT Pharmaceuticals (Nasdaq: SXTC) will effect a 1-for-150 share consolidation of its Class A ordinary shares, effective February 3, 2026. The company expects Class A shares to trade on Nasdaq under SXTC with new CUSIP G2161P165 at market open on that date.
Prior to consolidation 143,693,892 Class A shares were outstanding; after consolidation approximately 957,960 shares are expected. Fractional shares will be rounded up. Outstanding options, warrants and purchase rights will be adjusted proportionately. Shareholders holding shares through brokers will see automatic adjustments; contact Transhare Corporation for transfer-agent support.
Loading…
Loading translation…
Positive
- Share count reduced from 143,693,892 to ~957,960 shares
- Post-consolidation trading continues on Nasdaq under the same ticker SXTC
Negative
- Fractional shares rounded up, slightly increasing post-consolidation share count
- Outstanding options and warrants will be adjusted, creating administrative complexity
-22.00%
Since News
$0.04
Last Price
$0.04
$0.07
Day Range
-$2M
Valuation Impact
$6M
Market Cap
0.1x
Rel. Volume
Following this news, SXTC has declined 22.00%, reflecting a significant negative market reaction.
Our momentum scanner has triggered 10 alerts so far, indicating notable trading interest and price volatility.
The stock is currently trading at $0.04.
This price movement has removed approximately $2M from the company’s valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Share consolidation ratio
1-for-150
Ordinary share consolidation effective February 3, 2026
Pre-consolidation shares
143,693,892 shares
Class A ordinary shares outstanding before consolidation
Post-consolidation shares
approximately 957,960 shares
Class A ordinary shares expected after consolidation
Effective date
February 3, 2026
Date share consolidation becomes effective and trading on new basis
Current price
$0.05
Pre-news close vs. consolidation announcement
52-week high
$7.84
Pre-news price sat 99.36% below this level
Shelf registration capacity
$600,000,000
Form F-3 shelf filed November 10, 2025
Market cap
$8,833,915
Pre-news equity value at $0.05 share price
$0.0500
Last Close
Volume
Volume 34,603,545 is slightly below the 20-day average of 35,892,605 (relative 0.96x).
normal
Technical
Pre-news price 0.05 was trading well below the 200-day MA at 1.51, and 99.36% below the 52-week high of 7.84.
SXTC’s pre-news weakness contrasted with mixed peer moves: DERM and IRWD were modestly higher (1.08%, 1.67%), while OGI, TKNO, and BIOA were down between 2–3%. No peers appeared in the momentum scanner, pointing to a stock-specific setup ahead of the share consolidation.
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 |
AI initiative |
Positive |
+10.2% |
Announced AI Insight Initiative for TCM raw-material supply chain optimization. |
| Jan 09 |
Capital raising |
Negative |
-87.9% |
Announced $10M registered direct offering at $0.15 per share with warrants. |
| Jan 08 |
AI initiative |
Positive |
-37.5% |
Launched strategic AI Insights Initiative for portfolio planning and AI clinics. |
Recent SXTC news has driven large, often negative price swings, with capital-raising activity on Jan 9 followed by a sharp selloff and mixed reactions to AI-related strategic announcements.
Over the past month, SXTC issued several material updates. On Jan 8 and Jan 15, the company announced AI-focused initiatives aimed at optimizing its TCM portfolio and supply chain, with one update followed by a 10.18% gain and the other by a 37.5% decline. On Jan 9, a $10 million registered direct offering coincided with an 87.92% drop. Today’s share consolidation follows this dilution and steep price erosion.
$600,000,000
registered capacity
SXTC has an effective Form F-3 shelf filed on Nov 10, 2025, allowing it to offer up to $600,000,000 in various securities. The shelf has already been used once via a 424B5 offering on Jan 12, 2026, underscoring an established mechanism for additional capital raises.
The stock is dropping -22.0% following this news. A negative reaction despite the mechanical nature of a 1-for-150 share consolidation would fit SXTC’s recent pattern of sharp declines around structural changes, including the 87.92% drop after the January 9 offering. Pre-news, the stock traded at $0.05, far below the $7.84 52-week high. The consolidation follows heavy dilution under an active $600,000,000 shelf, which may keep pressure on sentiment.
cusip number
regulatory
“under the symbol “SXTC” with the new CUSIP number G2161P165”
A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.
stock options
financial
“All outstanding stock options, warrants and other rights to purchase the Company’s”
Stock options are agreements that give a person the right to buy or sell a company’s stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
warrants
financial
“All outstanding stock options, warrants and other rights to purchase the Company’s”
Warrants are special documents that give you the right to buy a company’s stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company’s stock price goes up.
transfer agent
regulatory
“or the Company’s transfer agent, Transhare Corporation, by calling +1 303-662-1122”
A transfer agent is a financial service that keeps the official record of who owns a company’s shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.
AI-generated analysis. Not financial advice.
TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) — China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 3, 2026. Upon the market opening on February 3, 2026, the Company’s Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P165.
Prior to the Share Consolidation, 143,693,892 Class A ordinary shares are issued and outstanding. As a result of the Share Consolidation, every 150 shares (or part thereof) will be combined into one (1) share, with fractional shares rounded up to the next whole share, and approximately 957,960 Class ordinary shares will be issued and outstanding after the Share Consolidation. The Company is authorized to issue an unlimited number of shares, divided into two Classes consisting of: (i) Class A ordinary shares with no par value and (ii) Class B ordinary shares with no par value. All outstanding stock options, warrants and other rights to purchase the Company’s Class A ordinary shares will be adjusted proportionately as a result of the Share Consolidation.
Upon the effectuation of the Share Consolidation, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Consolidation. Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company’s transfer agent, Transhare Corporation, by calling +1 303-662-1122.
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. The Company’s actual results may differ materially from those expressed in any forward-looking statements as a result of various factors and uncertainties. The reports filed by the Company with the Securities and Exchange Commission discuss these and other important factors and risks that may affect the Company’s business, results of operations and financial conditions. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com
FAQ
What does the 1-for-150 share consolidation mean for SXTC shareholders?
It combines every 150 Class A shares into one post-consolidation share. According to the company, shareholders will hold fewer shares with proportionately higher per-share amounts, and fractional shares will be rounded up to the next whole share.
When will SXTC shares trade on a post-consolidation basis on Nasdaq?
SXTC shares will trade on a post-consolidation basis beginning at the market open on February 3, 2026. According to the company, the new CUSIP will be G2161P165 and the ticker remains SXTC.
How many SXTC Class A shares will be outstanding after the consolidation?
Approximately 957,960 Class A ordinary shares are expected to be outstanding after the consolidation. According to the company, this follows consolidation of 143,693,892 pre-consolidation shares at a 1-for-150 ratio.
Will my SXTC stock held in a brokerage account be adjusted automatically?
Yes, shares held through banks, brokers or nominees will be adjusted automatically to reflect the share consolidation. According to the company, beneficial holders should contact their broker or Transhare Corporation for any transfer-agent questions.
How will outstanding SXTC options and warrants be affected by the consolidation?
All outstanding stock options, warrants and rights will be adjusted proportionately as a result of the consolidation. According to the company, exercise prices and share counts of those instruments will be changed to reflect the 1-for-150 ratio.
